Compugen Ltd (CGEN)
Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on researching, developing, and commercializing therapies and product candidates in Israel, the United States, and Europe. Its pipeline includes several immuno-oncology programs, such as COM701, an anti-PVRIG antibody; COM902, an anti-TIGIT antibody; Bapotulimab, an antibody targeting ILDR2; Rilvegostomig, an anti-PD-1/TIGIT bispecific antibody; and COM503, an antibody designed to block the interaction between IL-18 binding protein and IL-18. The company’s portfolio spans programs in Phase 1 and Phase 3 development, alongside earlier-stage preclinical candidates aimed at immune resistance mechanisms. Compugen also has collaboration and licensing agreements with Bristol-Myers Squibb, AstraZeneca, and Gilead Sciences related to selected development programs. Founded in 1993, the company is headquartered in Holon, Israel.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CGEN
|
$2.99
|
19.9% Upside
|
Undervalued
|
$4.60
|
84.7% Upside
|
Bargain
|
Excellent
|
0.0%
|
November 16, 2026
|
6.6x
|
2.6x
|
3.1x
|
235.9 M
|
110.7 M
|
1.3%
|
97.8%
|
0.6
|
79.9%
|
